# HosenCare Brothers

> HosenCare Brothers is a VC fund backing Biotechnology, Medical and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Apr 2023
- Lead investor: 20%
- Last updated: Aug 2026
- Website: http://www.hosencare.com/

HosenCare Brothers is a venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Agriculture | 1 | 20% |
| Health Care | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Series B | 2 | 40% |
| Series D | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 80% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Wimi bio | Wimi Bio is a high-tech enterprise focusing on the innovative research and development of gene editing and biological breeding technologies. |  | Seed | Apr 25, 2023 |  |
| Weimai Medical | Weimai Medical is an all-inclusive resource for minimally invasive and non-invasive energy medicine solutions. | $14.3M | Seed | Sep 19, 2022 |  |
| InxMed | InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $50M | Series B | Mar 03, 2022 |  |
| Simcere Pharma | Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million. | $93.8M | Series B | Jun 04, 2021 |  |
| Denovo Biopharma | Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stageclinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. | $42.5M | Series D | Dec 10, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Jolmo Capital](https://shizune.co/investors/profile/jolmo-capital-management) — VC Fund, 2 deals together
- [Yingke Capital](https://shizune.co/investors/profile/yingke-capital) — VC Fund, 2 deals together
- [AIHC Capital](https://shizune.co/investors/profile/aihc-capital) — VC Fund, 1 deal together
- China Resources Pharmaceutical Group — VC Fund, 1 deal together
- [CICC Qide](https://shizune.co/investors/profile/cicc-qide) — VC Fund, 1 deal together
- CITIC Medical Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does HosenCare Brothers invest in?

HosenCare Brothers invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did HosenCare Brothers last invest?

The most recent investment recorded for HosenCare Brothers closed in Apr 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co